Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

15.01 -0.26 (-1.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Arcutis Concludes Dosing In Late-Stage Itchy Skin Study, Anticipates Regulatory Submission By Next Year
Arcutis Biotherapeutics (NASDAQ: ARQT) has completed the enrollment of subject in its INTEGUMENT-2 pivotal Phase 3 trial of roflumilast cream 0.15% in adults and children with Atopic dermatitis (AD). 
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients... 
Via Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume. 
Via Benzinga
Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session
Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday. 
Via Benzinga
Analyst Ratings for Arcutis Biotherapeutics
Over the past 3 months, 4 analysts have published their opinion on Arcutis Biotherapeutics (NASDAQ:ARQT) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday
Gainers Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares jumped 187.3% to close at $48.03 on Monday after gaining around 18% on Friday. 
Via Benzinga
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap Of Friday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Arcutis Gets FDA Nod For Plaque Psoriasis Candidate, Sees Commercial Launch In Mid-August
The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ: ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in... 
Via Benzinga
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
7 Biotech Stocks to Buy for Q3
These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential. 
Via InvestorPlace
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. 
Via Benzinga
Mizuho Sees Buying Opportunity Despite Weakness In This Skin-Disease Focused Stock
Mizuho remains bullish on Arcutis Biotherapeutics Inc (NASDAQ: ARQT). It sees buying opportunity in the weakness as the company heads into 2H of 2022 with four potentially transformative catalysts for... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
88 Biggest Movers From Yesterday
Gainers The Very Good Food Company Inc. (NASDAQ: VGFC) shares jumped 118.2% to close at $0.2950 on Wednesday as the company announced it increased retail distribution across Canada with Loblaw... 
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers The Very Good Food Company Inc. (NASDAQ: VGFC) gained 178.3% to $0.3762 as the company announced it increased retail distribution across Canada with Loblaw Companies. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Arcutis Secures $225M Debt Financing To Fund Potential Launch Of Roflumilast
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) has obtained a $225 million term loan facility from SLR Capital Partners (SLR). This additional capital... 
Via Benzinga
Arcutis' Roflumilast Cream For Psoriasis Goes Under FDA Review
The FDA has accepted Arcutis Biotherapeutics Inc's (NASDAQ: ARQT) marketing application seeking approval for roflumilast cream for psoriasis in adults and... 
Via Benzinga
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug... 
Via Benzinga
5 Stocks To Watch For December 23, 2021
Some of the stocks that may grab investor focus today are: Banner Corporation (NASDAQ: BANR) reported a buyback of 1.71 million shares, which is the equivalent of around 5% of... 
Via Benzinga
Is Now the Time to Bet on Arcutis Biotherapeutics?
Management has high hopes for the company's treatment candidates for dermatological conditions, but can they get one to market before its cash cushion is depleted? 
Via The Motley Fool
Arcutis Stops ARQ-252 Vitiligo Trial After Formulation-Related Observations In Chronic Hand Eczema Study
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) will terminate the Phase 2a trial evaluating ARQ-252 as a potential treatment for vitiligo. The study was ... 
Via Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2021
Upgrades For Taiwan Semiconductor Manufacturing Co Ltd (NYSE: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 27, 2021
Upgrades Craig-Hallum upgraded the previous rating for NVIDIA Corp (NASDAQ:NVDA) from Hold to Buy. In the first quarter, NVIDIA showed an EPS of $3.66, compared to $1.80... 
Via Benzinga
55 Biggest Movers From Friday
Gainers Brooklyn ImmunoTherapeutics, Inc. (NYSE: BTX) jumped 45.5% to close at $49.80 on Friday after dropping around 22% on Thursday. Brooklyn ImmunoTherapeutics acquired... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Motus GI Hldgs (NASDAQ:MOTS) stock moved upwards by 30.17% to $1.42 during Friday's regular session. As of 12:31 EST, this security is trading at a volume of... 
Via Benzinga
38 Stocks Moving In Friday's Mid-Day Session
Gainers Image Sensing Systems, Inc. (NASDAQ: ISNS) rose 29.2% to $5.93 after the company announced it initiated a quarterly dividend of $0.12 per share, authorized a 220,000... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.